TY  - JOUR
AU  - Arias de la Rosa, Ivan
AU  - Lopez-Montilla, Maria Dolores
AU  - Roman-Rodriguez, Cristobal
AU  - Perez-Sanchez, Carlos
AU  - Gomez-Garcia, Ignacio
AU  - Lopez-Medina, Clementina
AU  - Ladehesa-Pineda, Maria Lourdes
AU  - Abalos-Aguilera, Maria Del Carmen
AU  - Ruiz, Desiree
AU  - Patiño-Trives, Alejandra Maria
AU  - Luque-Tevar, Maria
AU  - Añon-Oñate, Isabel
AU  - Perez-Galan, Maria Jose
AU  - Guzman-Ruiz, Rocio
AU  - Malagon, Maria M
AU  - Lopez-Pedrera, Chary
AU  - Escudero-Contreras, Alejandro
AU  - Collantes-Estevez, Eduardo
AU  - Barbarroja, Nuria
PY  - 2022
DO  - 10.1111/joim.13447
UR  - http://hdl.handle.net/10668/19994
T2  - Journal of internal medicine
AB  - (1) To evaluate clinical and molecular cardiovascular disease (CVD) signs and their relationship with psoriatic arthritis (PsA) features and (2) to identify a clinical patient profile susceptible to benefit from methotrexate (MTX) and/or apremilast...
LA  - en
PB  - Wiley-Blackwell Publishing
KW  - Apremilast
KW  - Cardiometabolic profile
KW  - Cardiovascular risk
KW  - Insulin resistance
KW  - Methotrexate
KW  - Obesity and disease activity
KW  - Psoriatic arthritis
KW  - Antirheumatic agents
KW  - Arthritis, psoriatic
KW  - Cardiovascular diseases
KW  - Cross-sectional studies
KW  - Humans
KW  - Leukocytes, mononuclear
KW  - Methotrexate
KW  - Thalidomide
TI  - The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.
TY  - Research article
VL  - 291
ER  -